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Background: The pathogenesis of pulmonary fibrosis remains poorly understood. The Wnt signaling pathway
regulates fibrogenesis in different organs. Here, we studied the role of two extracellular Wnt antagonists, secreted
frizzled-related protein-1 (SFRP1) and frizzled-related protein (FRZB) on lung fibrosis in vitro and in vivo. For this
purpose, we used an alveolar epithelial cell line and a lung fibroblast cell line, and the bleomycin-induced lung
fibrosis model, respectively.
Results: During the course of bleomycin-induced lung fibrosis, Sfrp1 and Frzb expression are upregulated.
Expression of Sfrp1 appears much higher than that of Frzb. In vitro, recombinant SFRP1, but not FRZB, counteracts
the transforming growth factor β1 (TGFβ1)-induced upregulation of type I collagen expression both in pulmonary
epithelial cells and fibroblasts. Both SFRP1 and FRZB inhibit the TGFβ1-induced increase of active β-catenin, but do
not influence the TGFβ1-induced phosphorylation levels of SMAD3, positioning Wnt signaling activity downstream
of the active TGFβ signal in lung fibroblasts, but not in alveolar epithelial cells. In vivo, Sfrp1−/− and Frzb−/− mice
showed identical responses to bleomycin in the lung compared to wild-type controls.
Conclusions: Although SFRP1 counteracts the effect of TGFβ1 in pulmonary cells in vitro; loss of neither SFRP1 nor
FRZB alters fibrotic outcomes in the lungs in vivo. The lack of in vivo effect in the absence of specific SFRPs suggests
functional redundancy within this family of Wnt antagonists.
Keywords: Transforming growth factor-beta, WNT signaling, Secreted frizzled related proteins, Bleomycin,
Pulmonary fibrosis, Skin fibrosisBackground
Interstitial lung disease can occur in association with
connective tissue diseases such as systemic sclerosis
(SSc), can specifically present as idiopathic pulmonary fi-
brosis (IPF), or may be caused by exposure to environ-
mental toxins. The pathophysiology of lung fibrosis
remains poorly understood and regardless its cause, the
disease processes are associated with significant morbidity
and mortality [1]. The current concept suggests injury-
induced activation of epithelial cells, with deregulated
repair causing inappropriate alveolar regeneration and
impaired epithelial-mesenchymal crosstalk, resulting in* Correspondence: rik.lories@uz.kuleuven.be
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article, unless otherwise stated.mesenchymal cell activation, migration, and progressive
lung fibrosis [2]. Activation of signaling pathways that
have critical roles during embryonic development is
thought to play a central role in this abnormal repair re-
sponse. In this context, increasing evidence supports a
crucial part for the Wnt (wingless-type like) signaling
pathway [3].
Wnt ligands are lipid-modified, cysteine-rich glycopro-
teins that bind to frizzled (Fz) receptors. The formation of
a ligand-receptor complex associated with a co-receptor
LRP5 or LRP6 (low-density lipoprotein receptor-related
protein) leads to activation of the canonical Wnt cas-
cade with key mediator β-catenin that upon accumula-
tion translocates to the nucleus and regulates gene
transcription [4,5]. In addition, Wnts can also activate
non-canonical cascades such as the Wnt/JNK (Jun-
amino-terminal kinase), Wnt/Ca2+, or Wnt/PKA (protein
kinase A) pathway [6].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Wnt signaling in fibrotic lung disease. Recent data have
shown that inhibition of GSK3β, an enzyme that inhibits
accumulation of ß-catenin, increases collagen release
from SSc fibroblasts and aggravates both bleomycin-
induced skin fibrosis and skin fibrosis in Tsk1 mice [7],
potentially through an endothelin-dependent mechanism
[8]. Furthermore, activation of Wnt signaling through
downregulation of the Wnt antagonist Dickkopf (Dkk) is
required for TGFβ-mediated fibrosis, positioning Wnt
signaling downstream of TGFβ in fibroblasts [9]. In-
creased nuclear β-catenin has been detected in lung tissue
from patients with IPF and systemic sclerosis-associated
lung fibrosis, compared to healthy controls [10,11]. Differ-
ent Wnts and Wnt target genes are upregulated in IPF
lungs and specifically localized to bronchial and alveolar
type II epithelial cells (WNT1, WNT3A) or endothelial
and vascular smooth muscle cells (WNT1) [12]. Further
evidence for active WNT signaling in lung fibrosis came
from microarray analysis of IPF lungs, confirming en-
richment of WNT-related genes encompassing ligands
(WNT2, WNT5a), receptors (FZ7, FZ10), antagonists
(SFRP1), and target genes (LEF1) [13]. Results from dif-
ferent microarray analysis studies all indicate an upreg-
ulation of SFRP1 and FRZB in fibrotic lung disease
(IPF). In addition, some animal model data are available.
Wisp1 (WNT1-inducible signaling protein 1) is upregu-
lated in bleomycin induced murine lung fibrosis, as well
as in human IPF. Neutralization of WISP1 [14] or inhib-
ition of Wnt/β-catenin/CREB (cyclic adenosine mono-
phosphate (cAMP) response element binding protein)
binding protein (CBP) signaling attenuates and reverses
bleomycin-induced pulmonary fibrosis [15].
Endogenous modulators and antagonists regulate Wnt
signaling in the extracellular space and at the level of the
receptors. Secreted frizzled-related proteins (SFRPs) bind
Wnt ligands in the extracellular space, thereby theoretic-
ally preventing ligand-receptor interaction. Frizzled-related
protein (FRZB) was the founding member of this family
[16-18] and confirmed to bind xWNT8 and antagonize
its activity in Xenopus. The SFRP family encompasses
five members in humans, SFRP1 to SFRP5, with SFRP3
a synonym for FRZB. Sequence comparison and phylo-
genetic analysis have demonstrated SFRP1, SFRP2, and
SFRP5 to form a subgroup that differs from the one
formed by FRZB and SFRP4 [19]. Recent evidence sup-
ports the view that FRZB and other SFRPs do not
merely act as antagonists but have more complex effects
on Wnt gradient formation, including the extension of
the ligand signaling range [20,21].
In this work, we aimed to further understand the po-
tential role of SFRPs in lung fibrosis. We therefore stud-
ied the effect of SFRPs on lung fibrosis in in vitro and
in vivo models, including the effect caused by absence ofendogenous SFRP1 and FRZB in the bleomycin-induced
lung fibrosis model. We show that both Sfrp1 and Frzb
are upregulated during the course of bleomycin-induced
lung fibrosis. In vitro, SFRP1 reduces the TGFβ1-induced
upregulation of collagen expression in both pulmonary
fibroblasts and alveolar epithelial cells. In vivo, the absence
of SFRP1 or FRZB does not alter fibrotic outcomes in the
lung, suggesting functional redundancy.
Results
In bleomycin-induced lung fibrosis, canonical Wnt
signaling is active and Sfrp1 and Frzb are upregulated
Intratracheal bleomycin instillation results in pulmonary
fibrosis with excessive collagen deposition and obliter-
ation of alveolar structures (Figure 1A). Immunohisto-
chemistry demonstrated increased nuclear β-catenin in
fibrotic zones indicating active canonical Wnt signaling,
while this signal was absent in the PBS-treated lungs
(Figure 1B). We used gene expression analysis of the dif-
ferent Sfrps to study their dynamic profile in the
bleomycin-induced pulmonary fibrosis model. Sfrp1 and
Sfrp2 mRNA levels were 2 log-scales more abundant
than those of Frzb and Sfrp4. Sfrp5 could not be de-
tected. Sfrp1 levels were significantly increased at all
time points after bleomycin treatment but not different
between time points (Figure 1C) (2-way ANOVA P =
0.0015 for bleomycin vs. PBS, P >0.05 for time and inter-
action). Frzb levels were significantly and consistently in-
creased over time after bleomycin treatment (2-way
ANOVA P <0.0001 for bleomycin vs. PBS, P = 0.0248 for
time and P = 0.0154 for interaction). Sfrp2 and Sfrp4
levels were not different between groups or during the
course of the disease, with Sfrp2 relative expression simi-
lar to Sfrp1 and Sfrp4 levels similar to baseline Frzb. We
therefore further focused on SFRP1 and FRZB.
SFRP1, but not FRZB, reduces TGFβ1-induced collagen
upregulation in pulmonary fibroblasts and alveolar
epithelial cells
Activation of pulmonary fibroblasts is an important
process in lung fibrosis. In TGFβ1-stimulated fibroblast
MRC5 cells, SFRP1 significantly reduced TGFβ1-driven
Coll1α1 expression (Figure 2A). In contrast, this effect
was absent with FRZB stimulation (Figure 2B). Western
blot analysis showed that TGFβ1 stimulation in MRC5
cells results in increased phosphorylation of SMAD3,
but also increased active, dephosphorylated β-catenin
(Figure 3). Stimulation of MRC5 cells with Wnt antago-
nists SFRP1 (Figure 3A) or FRZB (Figure 3B) reduces
the active fraction of β-catenin. Both SFRP1 and FRZB
inhibit the TGFβ1-induced increase of active β-catenin,
but do not influence the TGFβ1-induced phosphorylation
levels of SMAD3, positioning Wnt signaling activity
downstream of the active TGFβ signal in lung fibroblasts.
Figure 1 WNT and SFRP dynamics in bleomycin-induced lung fibrosis. (A) Representative images lungs from WT mice, 4 weeks after PBS or
bleomycin instillation. (Hematoxylin-Eosin and Masson Trichrome staining) (B) β–catenin or goat IgG (negative control, 3rd panel)
immunohistochemistry, 4 weeks after intratracheal PBS or bleomycin instillation in WT mice. (C) Total lung gene expression level of Sfrp1, Sfrp2,
Frzb and Sfrp4 following bleomycin instillation (n = 4, except for bleomycin group at day 21 n = 2; data presented as mean and SEM of ΔCT
values normalized to Hprt expression).
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tribute to fibrosis. We therefore studied the effect of re-
combinant SFRP1 or FRZB and TGFβ1 stimulation on
alveolar epithelial cells (A549). Recombinant SFRP1 does
not alter baseline E-cadherin levels, nor the TGFβ1-Figure 2 Effect of SFRP1 and FRZB on pulmonary fibroblasts. (A) Gene
and SFRP1; (n = 3; data presented as mean and SEM). (B) Gene expression
(n = 3; data presented as mean and SEM) (*P <0.05 by one-way ANOVA aninduced downregulation of E-cadherin in A549 cells.
However, SFRP1 significantly reduced TGFβ1-induced
upregulation of coll1α1 (Figure 4A). FRZB did not alter
TGFβ1-induced alterations in E-cadherin or coll1α1 ex-
pression in A549 cells (Figure 4B). In contrast to ourexpression level of collagen1α1 in MRC5 cells, stimulated with TGFβ1
level of collagen1α1 in MRC5 cells, stimulated with TGFβ1 and FRZB
d post-hoc test vs TGFβ1-only stimulated cells).
Figure 3 Downstream signaling in pulmonary fibroblasts after SFRP1 and FRZB stimulation. Western blot of protein extracts from total
MRC5 cell lysates, stimulated with TGFβ1 and SFRP1 (A) or FRZB (B), labeled with antibodies against pSMAD3, total SMAD3, total β-catenin, active
β-catenin, and β-actin.
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active β-catenin in alveolar epithelial cells (Figure 5).Absence of Sfrp1 or Frzb does not affect fibrotic
responses in the bleomycin-induced lung fibrosis model
Based on these in vitro observations and the expression
profile during bleomycin-induced lung fibrosis, we fur-
ther studied the role of endogenous SFRP1 and FRZB
using the respective knockout mice compared to wild-
type (WT) littermates. The severity of pulmonary fibrosis,
induced by intratracheal bleomycin instillation, was identi-
cal in Sfrp1−/− mice compared to WT mice (Figure 6).
Histopathological Ashcroft score (Figure 6A), collagen
content (Figure 6B), pulmonary compliance (Figure 6C),
and end-expiratory volume (EEV), quantified by μCT
imaging (Figure 6D) were comparable between Sfrp1−/−
mice and WT mice. Likewise, upon instillation of bleo-
mycin, Frzb−/− mice have similar fibrotic responses
when compared to WT mice. Frzb−/− mice have an in-
creased Ashcroft score (Figure 7A) and increased lung
collagen content by bleomycin (Figure 7B), comparable
to WT controls.Discussion
Wnt signaling is crucial in embryonic lung development.
Growing evidence highlights a role for increased func-
tional Wnt signaling in fibrogenesis. Wnt pathway activ-
ity is tightly regulated at the extracellular level. SFRPs
are extracellular WNT antagonists that share sequence
similarity with the Fz receptors and bind WNT ligands,
preventing their interaction with their dedicated receptor
complex. Extracellular Wnt antagonists are molecules
of therapeutic interest to control Wnt signaling activity
and alter its oncogenic, pro-invasive, and fibrogenic
properties. In this work, we investigated the modulatory
roles of SFRP1 and FRZB in TGFβ-stimulated pulmon-
ary fibroblasts and epithelial cells. Next, we studied fi-
brotic responses in bleomycin-induced lung fibrosis in
mice lacking one SFRP family member, using Sfrp1−/−
and Frzb−/− mice.
In the bleomycin lung fibrosis model, we confirm the
presence of increased active canonical Wnt signal by
immunohistochemistry for β-catenin. Gene expression
analysis of whole lung lysates showed concurrent upreg-
ulation of the Wnt antagonists Sfrp1 and Frzb in the
bleomycin model. The related antagonists Sfrp1 and
Figure 4 Effect of SFRP1 and FRZB on alveolar epithelial cells. (A) Gene expression levels of E-cadherin and (B) collagen1α1 in A549 cells,
stimulated with TGFβ1 and SFRP1 (n = 3; data presented as mean and SEM). (C) Gene expression levels of E-cadherin and (D) collagen1α1 in A549
cells, stimulated with TGFβ1 and FRZB (n = 3; data presented as mean and SEM) (*P <0.05 by one-way ANOVA and post-hoc test vs. TGFβ1-only
stimulated cells).
Figure 5 Downstream signaling in alveolar epithelial cells after SFRP1 and FRZB stimulation. Western blot of protein extracts from total
A549 cell lysates, stimulated with TGFβ1 and SFRP1 (A) or FRZB (B), labeled with antibodies against total β-catenin and active β-catenin.
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Figure 6 Bleomycin-induced lung fibrosis in Sfrp1−/− mice. (A) Ashcroft score 4 weeks after PBS or bleomycin instillation, from WT mice (PBS
n = 5, BLM n = 6) and Sfrp1−/− mice (PBS n = 5, BLM n = 11). (B) Hydroxyproline content of left lungs 4 weeks after PBS or bleomycin instillation
from WT mice (PBS n = 4, BLM n = 5) and Sfrp1−/− mice (PBS n = 5, BLM n = 10). (C) Pulmonary compliance 4 weeks after PBS or bleomycin
instillation of WT mice (PBS n = 3, BLM n = 4) and Sfrp1−/− mice (PBS n = 6, BLM n = 11). (D) End-expiratory volume (EEV) 4 weeks after PBS or
bleomycin instillation, quantified by μCT imaging in WT mice (PBS n = 5, BLM n = 8) and Sfrp1−/− mice (PBS n = 5, BLM n = 11).
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However, only Sfrp1 and Frzb show dynamic changes in
their expression levels upon bleomycin instillation. We
therefore focused on SFRP1 and FRZB. In an attempt
to localize SFRP1 or FRZB protein in the bleomycin
model, we performed multiple immunohistochemistry
optimization steps, but were unable to eliminate false
positive background staining for both SFRPs. Western
blot analysis of whole lung lysates confirmed the in-
creased presence of SFRP1 in bleomycin-treated lungs,
but no band was detected for FRZB, not even in theFigure 7 Bleomycin-induced lung fibrosis in Frzb1−/− mice. (A) Ashcrof
n = 21, BLM n = 25) and Frzb−/− mice (PBS n = 15, BLM n = 18). (B) Hydroxy
from WT mice (PBS n = 5, BLM n = 5) and Frzb−/− mice (PBS n = 5, BLM n =positive recombinant protein control, indicating tech-
nical shortcomings. We hypothesize that both SFRPs
are upregulated in bleomycin-induced lung fibrosis, in
an attempt to control overactive canonical Wnt signaling.
We therefore studied the antifibrotic potential of both
SFRP1 and FRZB in a series of in vitro experiments.
In pulmonary fibroblasts, we confirm that an active
TGFβ1 signal results in downstream activation of canonical
Wnt signaling, which can be inhibited by exogenous ad-
ministration of SFRP1 and FRZB. In vitro, co-stimulation
of pulmonary fibroblasts with both TGFβ1 and SFRP1 butt score 4 weeks after PBS or bleomycin instillation, from WT mice (PBS
proline content of left lungs 4 weeks after PBS or bleomycin instillation,
5).
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collagen expression. These data support the notion of a
modulatory role of SFRP1 and FRZB in the downstream
signaling events of TGFβ in fibroblasts. The differential ef-
fect of SFRP1 and FRZB on TGFβ1-driven collagen expres-
sion is noteworthy as both SFRPs equally abolish the
activation of β-catenin. Wnts signal both through canonical
β-catenin dependent pathways, and through non-canonical
pathways. SFRPs are known to be able to modulate both.
In recent years, the interest in this SFRP family has grown,
as increasing evidence indicates that SFRPs are not only
Wnt binding proteins, but can also antagonize one an-
other’s activity, bind to FZD, interact with other receptors
or matrix molecules and interfere with BMP signaling, in-
creasingly expanding the biological relevance of these mol-
ecules [19,22]. The pleiotropic effects of the SFRP family
members might explain this disparity. Interestingly, in pul-
monary epithelial cells, TGFβ induces EMT, evident by a
downregulation of epithelial and upregulation of mesen-
chymal markers, but this effect does not alter β-catenin
phosphorylation levels. Likewise, in epithelial cells, SFRP1,
but not FRZB, reduces the profibrotic effects of TGFβ.
From these in vitro datasets, we concluded that both
SFRP1 and FRZB could alter TGFβ signaling in fibro-
blasts. As both Sfrp1−/− and Frzb−/− mice were available,
we decided to study the potential modulatory roles of
both SFRPs in the bleomycin-induced model, using a
loss-of-function approach. Sfrp1−/− mice have impaired
distal lung development with dilation of the alveolar ducts.
This finding was shown to be non-progressive, not alter-
ing lung mechanics, and thus considered a developmental
defect, not an ongoing destructive process [23]. In our
study we did not find differences in base-line parameters
between Sfrp1−/− or Frzb−/− mice and littermates, includ-
ing pulmonary function tests and μCT imaging.
In our experiments, loss of neither SFRP1 nor FRZB
in Sfrp1−/− or Frzb−/− mice alters fibrotic outcomes com-
pared to WT mice. These findings might be explained
by functional redundancy between the different SFRP
subgroup members, where other SFRP family members
could functionally compensate for the loss of one mem-
ber. Indeed, different SFRP knockout animals have only
discrete phenotypes, whereas double knockout animals
have been reported with severe developmental abnor-
malities. As we have both Sfrp1−/− and Frzb−/− mice
available, we have tried to setup double knockout ani-
mals. However, live births of Sfrp1−/−/Frzb−/− double
knockout mice are very rare, suggesting the existence of
developmental problems that are currently under further
investigation and go beyond the purpose of this study.
Conclusion
Wnt and TGFβ signaling play a central role in fibrogen-
esis. In this work, we examined the role of two secretedWnt antagonists, SFRP1 and FRZB. We show that
SFRP1 counteracts the profibrotic effect of TGFβ1 in
pulmonary cells in vitro. However, loss of neither SFRP1
nor FRZB alters fibrotic outcomes in the lungs in vivo.
The lack of in vivo effect in the absence of specific
SFRPs suggests functional redundancy within this family
of Wnt antagonists.Methods
Animals
Eight-week-old male Sfrp1−/− (a gift from Jeff Rubin,
NIH) and Frzb−/− mice [24], both on a C57BL/6 background
were used. WT littermates served as controls. Weights
were not different between the strains (mean +/− standard
error (SE) WT (n = 57) 24.09 +/− 0.25 g, Sfrp1−/− (n = 19)
23.05 +/− 0.54 g, Frzb−/− (n = 33) 23.79 +/− 0.29 g). Mice
were genotyped by PCR using DNA obtained from tail
biopsy tissues. WT and Frzb−/− knockout alleles were
amplified using forward primer p1 (5′-TGAACTTTG
CCCGACCTCTGAG-3′) and reverse primer p2 (5′-
GATCGCTCGGATCACTTGTTGG-3′) or using forward
primer p3 (5′-CTGATGTCTCTGCCAGAGCGAG-3′)
and reverse primer p4 (5′-TGGACGTAAACTCCTCT
TCAGACC-3′), respectively. WT and Sfrp1−/− knockout
alleles were amplified as previously described [25]. The
KU Leuven Ethical Committee for animal research ap-
proved all experiments.Bleomycin-induced lung fibrosis
Lung fibrosis was induced by intratracheal instillation of
0.05 U bleomycin (BLM) (Sanofi-Aventis), dissolved in
50 μL of sterile phosphate buffered saline (PBS), or PBS
as a control. An incision was made in the shaved anter-
ior neck region. Blunt dissection of the salivary glands
and the pretracheal muscles along the midline exposed
the trachea. The animal was placed in 70° upright pos-
ition. A 0.3 mL syringe with a 30G needle was placed
between two tracheal cartilaginous rings after which
BLM or PBS could slowly be injected. The wound was
closed with Vicryl 5.0. Pulmonary fibrosis was induced
in WT, Sfrp1−/−, and Frzb−/− mice (Sfrp1−/−: BLM n = 11,
PBS n = 5, WT littermates: BLM n = 6, PBS n = 5; Frzb−/−
BLM n = 18, PBS n = 15, WT littermates: BLM n = 25,
PBS n = 21). Four weeks after baseline induction, mice
were scanned with a desktop in vivo micro-computed
tomography (μCT) imager and subsequently invasive pul-
monary function tests were performed using the flexiVent®
SCIREQ system. Mice were sacrificed and pulmonary
tissue was collected for histopathology, collagen quanti-
fication, and gene expression analysis. For the time-
course experiment, BLM was administered and mice
were sacrificed 7, 14, and 21 days after induction.
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Mice were scanned in supine position using a desktop
in vivo small animal μCT (SkyScan 1076, software ver-
sion 3.2, Kontich, Belgium) at day 28 after induction.
Images were acquired and retrospective respiratory gat-
ing applied. Images were acquired in list-mode with the
following parameters: 50 kVp X-ray source voltage,
180 μA current, a composite X-ray filter of 0.5 mm alu-
minium, 120 ms camera exposure time per projection, 9
projections per view, 23 × 35 mm field of view, acquiring
projections with 0.7° increments over a total angle of 180°,
producing images with a real pixel size of 35 μm. Total
scanning time was approximately 12 min, resulting in a
radiation dose of 813 mGy. Tomograms were recon-
structed using NRecon software (version 1.6.1.3, Sky-
Scan). Images were analyzed using CTAn software
(version 1.10.0.0, SkyScan) using an automated and vali-
dated aerated lung volume segmentation algorithm, calcu-
lating end-expiratory lung volume (EEV) (corresponding
to functional residual volume (FRV)) [26].
Pulmonary function tests
Mice were anesthetized with an intraperitoneal injection
of pentobarbital (70 mg/kg) (CEVA) to suppress spon-
taneous breathing. After a tracheostomy, the mice were
connected to the flexiVent system (SCIREQ). The computer-
controlled small animal apparatus ventilated the mice
quasi-sinusoidally with a tidal volume of 10 mL/kg at
a frequency of 150 breaths/min and a positive end-
expiratory pressure of 2 cmH2O to achieve a mean lung
volume close to that during spontaneous breathing. On
the flexiVent we performed a Snapshot perturbation.
Each time before performing this perturbation, a total
lung capacity perturbation (TLC) was carried out to
normalize the lungs. The data from the TLC perturb-
ation were not used. The snapshot perturbation was
performed until three acceptable measurements (coeffi-
cient of determination >0.95) were recorded in each in-
dividual subject, of which an average was calculated.
The snapshot perturbation was imposed to measure
resistance (R), compliance (C), and elastance (E) of the
whole respiratory system (airways, lung, and chest wall).
Only the data of the C are presented in the results [27].
Histological analysis
After completion of invasive pulmonary function tests,
mice were euthanized with pentobarbital overdose. The
tracheal cannula was removed, the chest cavity was opened,
and heart and lungs were removed en bloc. The left lung
was collected for histopathology, inflated with 400 μL of
10% formalin/PBS via the left main bronchus and fixed in
formalin for 24 h. After paraffin embedding, 5 μm sections
were cut throughout the whole lung. Five sections, with
1 mm interval, were stained with hematoxylin-eosin (H &E) or Masson-Trichrome. The semi-quantitative Ashcroft
score was used to score pulmonary fibrosis [28]. In
short, upon 100x magnification, each successive field
was given a score ranging from 0 (normal lung) to 8
(total fibrous obliteration of the field). All scores from
five sections were averaged.Immunohistochemistry
For immunohistochemistry, sections were quenched
with 3% H2O2/H2O. Antigen retrieval was performed in
a 10 mM sodium citrate buffer and sections were prein-
cubated with donkey serum (10% in PBS). Sections were
incubated overnight at 4°C with primary antibody against
β-catenin (1:200 dilution; Santa Cruz). Negative control
studies were performed with species-specific IgG (Jackson
ImmunoResearch). Secondary antibodies were horseradish
peroxidase-conjugated antibodies (1:200 dilution; Jackson
ImmunoResearch).Hydroxyproline assay
In the respective experiments, right lungs were collected
for hydroxyproline quantification and stored at −80°C
for later analysis. Hydroxyproline quantification was per-
formed as described [29]. Lungs were hydrolyzed for 3 h
in 6 M HCl at 120°C. After cooling down for 15 min,
pH was neutralized (pH 6 to 7) using NaOH. Samples
were diluted 1/20 in sterile H20. Free hydroxyproline
was oxidized with Chloramine-T for 20 min after which
the oxidation reaction was stopped using 70% perchloric
acid. Ehrlich’s reagent was added and samples heated for
20 min in a 60° water bath. After cooling down for
5 min, absorbance was measured at 570 nm and concen-
trations were calculated based on a standard curve.Cell culture
A549 lung adenocarcinoma cells were cultured in Dul-
becco’s Modified Eagle Medium (DMEM)/Glutamax
(4.5 g/L of glucose) (Invitrogen) supplemented with 10%
fetal bovine serum (FBS) (Gibco), antibiotic-antimycotic
solution (100 units/mL penicillin, 100 μg/mL strepto-
mycin, and 0.25 μg/mL amphotericin B; Invitrogen), and
sodium pyruvate (Gibco). MRC5 cells were cultured in
Minimal Essential Medium Eagle (EMEM) supplemented
with 10% FBS, minimal essential amino acids, antibiotic-
antimycotic solution, and L-glutamine. Cells were allowed
to attach for 24 h, after which they reached 80% con-
fluency and were serum starved for another 24 h. Cells
were stimulated with 0 to 5 ng/mL TGFβ1 (R & D Sys-
tems), 0 to 100 ng/mL of human recombinant SFRP1 of
FRZB (R & D Systems) for 24 h for gene expression
analysis.
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polymerase chain reaction
Total RNA was extracted from lung homogenates and
cell lysates using NucleoSpin RNA isolation kit (Machery
Nagel) and reverse-transcribed using First strand cDNA
synthesis kit (Fermentas). Gene expression levels were
quantified using Taqman Assays-on-Demand (Applied
Biosystems). Expression was normalized to hypoxanthine-
guanine phosphoribosyltransferase (Hprt) for in vivo
experiments, and to glyceraldehyde 3-phosphate de-
hydrogenase (Gapdh) for in vitro experiments, and sub-
sequently normalized to the control condition using the
comparative cycle threshold method (ΔΔCT).
Protein extraction and western blotting
Total cell lysates were homogenized in 300 μL Cell Ex-
traction Buffer (Invitrogen) supplemented with 5% Pro-
teinase Inhibitor Cocktail (Sigma Aldrich) and 1 mM
phenylmethylsulfonyl fluoride (PMSF) (Sigma Aldrich).
A total of 5 (MRC5 cells) μg or 7.5 (A549 cells) μg of
proteins were loaded onto a 4-12% Bis-Tris gel (Invitro-
gen). Electrophoresis was carried out in running buffer
(NuPAGE MES SDS running buffer (20×); Invitrogen) at
150 V for 70 min. Proteins were transferred onto a poly-
vinylidene difluoride membrane using semi-dry transfer
(Bio-Rad) for 70 min. Non-specific binding sites were
blocked for 75 min with 5% skimmed milk powder in
TBS-Tween (TBST). Blots were probed with primary
antibodies overnight at 4°C. The antibodies against ac-
tive β-catenin (#05-665, Millipore) and total β-catenin
(#610154, BD Biosciences) were used at dilutions 1/
1,000 and 1/2,000, respectively in 5% skimmed milk
powder in TBST. The antibodies against phosphorylated
SMAD3 (#9520, Cell signaling) and total SMAD3
(#9523, Cell signaling) were used at dilution 1/1,000 in
5% Bovine Serum Albumin (BSA) in TBST. Stripped
blots were probed with Actin (#A2066, Sigma Aldrich)
in TBST 5% BSA at 1/8,000 as loading control. Next
day, the membrane was incubated with a horseradish
peroxidase (HRP)-conjugated goat anti-mouse secondary
antibody (dilution 1/10,000 in 5% skimmed milk powder
in TBST) (Jackson ImmunoResearch) for active and total
β-catenin and anti-rabbit IgG conjugated with HRP
abtibody (dilution 1/50,000 in blocking buffer) (Jackson
ImmunoResearch) for phosphorylated and total SMAD3
and Actin, for 1 h at room temperature. All washes were
performed with TBST (3 × 10 min).
Statistical analysis
Data were analyzed using GraphPad Prism 6.0 (Graphpad).
Data were analyzed by one-way ANOVA with Holm-Sidak
post-hoc test for multiple group comparisons or two-way
ANOVA where appropriate. P values <0.05 were consid-
ered significant.Abbreviations
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protein; CREB: cAMP response element binding protein; Dkk: Dickkopf;
DMEM: Dulbecco’s Modified Eagle Medium; E: Elastance; EEV: End-expiratory
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volume; FRZB: Frizzled-related protein; Fz: Frizzled; GAPDH: Glyceraldehyde
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guanine phosphoribosyltransferase; HRP: Horseradish peroxidase;
IPF: Idiopathic pulmonary fibrosis; JNK: Jun-amino-terminal kinase; LRP:
Low-density lipoprotein receptor-related protein; MRC5: Lung fibroblast
cell line; PBS: Phosphate buffered saline; PKA: Protein kinase A;
PMSF: Phenylmethylsulfonyl fluoride; R: Resistance; SFRP1: Secreted
Frizzled related protein-1; SSc: Systemic sclerosis; TBST: TBS-Tween;
TGFβ1: Transforming growth factor β1; TLC: Total lung capacity;
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